ViroPharma To Release 2012 Fourth Quarter And Full Year Financial Results On February 27, 2013

 ViroPharma To Release 2012 Fourth Quarter And Full Year Financial Results On
                              February 27, 2013

PR Newswire

EXTON, Pa., Feb. 22, 2013

EXTON, Pa., Feb. 22, 2013 /PRNewswire/ --ViroPharma Incorporated's (Nasdaq:
VPHM) fourth quarter and full year financial results for 2012 are expected to
be released on Wednesday, February 27, 2013 before the open of the U.S.
financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m.
Eastern Time on the same day. During the conference call, ViroPharma
management will discuss the 2012 fourth quarter and full year financial
results and other business.

The press release and the live webcast of the conference call will be
accessible via ViroPharma's corporate website at
An audio archive will be available at the same address until March 15, 2013.
To participate in the conference call, please dial (800) 874-4559 (domestic)
and (302) 607-2019 (international). After placing the call, please tell the
operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercializing novel solutions for physician
specialists to address unmet medical needs of patients living with diseases
that have few if any clinical therapeutic options. ViroPharma is developing a
portfolio of therapeutics for rare and Orphan diseases including C1 esterase
inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency,
cytomegalovirus (CMV); and recurrent C. difficile infection (CDI). Our goal
is to provide rewarding careers to employees, to create new standards of care
in the way serious diseases are treated, and to build international
partnerships with the patients, advocates, and health care professionals we
serve. ViroPharma's commercial products address diseases including hereditary
angioedema (HAE), seizures, adrenal insufficiency and C. difficile-associated
diarrhea (CDAD); for full U.S. prescribing information on our products, please
download the package inserts at; the
prescribing information for other countries can be found at

ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of our
company's web site, The company encourages investors to
consult these sections, and the risk factors included in our periodic filings
with the Securities and Exchange Commission for more information on ViroPharma
and our business.

SOURCE ViroPharma Incorporated

Contact: Robert A. Doody, Director, Investor Relations, ViroPharma
Incorporated, +1-610-321-6290
Press spacebar to pause and continue. Press esc to stop.